Fatty liver disease (MASLD/MASH): open trials in Saudi Arabia

5 open trials have a site in Saudi Arabia. Registry data; only the trial team decides who can take part.

NCT06632444
LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis
Trial Treatment · Phase 3 · Boehringer Ingelheim
King Faisal Specialist Hospital and Research Center, Riyadh · King Abdulaziz Medical City, National Guard Health Affairs, Riyadh
Registry updated 2026-10-28
NCT06632457
LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis
Trial Treatment · Phase 3 · Boehringer Ingelheim
King Abdulaziz Medical City, National Guard Health Affairs, Riyadh · King Faisal Specialist Hospital and Research Center, Riyadh
Registry updated 2026-10-28
NCT07221188
A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH
Trial Treatment · Phase 3 · GlaxoSmithKline
Riyadh
Registry updated 2026-09-17
NCT07221227
A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH
Trial Treatment · Phase 3 · GlaxoSmithKline
Riyadh
Registry updated 2026-07-27
NCT05697991
Non-Alcoholic Fatty Liver Disease in a Saudi Cohort With Type 2 Diabetes Mellitus
Research · King Saud University
King Fahad Medical City, Riyadh
Registry updated 2023-10-05

This page is not medical advice. Talk to your doctor before contacting a trial.

LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis